This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CVS Health (CVS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of +23.13% and +5.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Establishment Labs (ESTA) delivered earnings and revenue surprises of 15.66% and 0.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Establishment Labs Holdings Inc. (ESTA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Establishment Labs (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Establishment Labs (ESTA) delivered earnings and revenue surprises of -58.06% and 0.64%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DocGo (DCGO) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
DocGo (DCGO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Establishment Labs (ESTA) delivered earnings and revenue surprises of 3.28% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics (SERA) delivered earnings and revenue surprises of -9.09% and 67.78%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Beats Q3 Earnings Estimates
by Zacks Equity Research
Avantor (AVTR) delivered earnings and revenue surprises of 4% and 0.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs (ESTA) delivered earnings and revenue surprises of -19.23% and 1.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs (ESTA) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs (ESTA) delivered earnings and revenue surprises of 10.77% and 4.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 16.84% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Establishment Labs Holdings Inc. (ESTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -55.56% and 5.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Soars 7.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Establishment Labs Holdings Inc. (ESTA): Can Its 14.3% Jump Turn into More Strength?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 4.41% and 2.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Brookdale (BKD) May 2023 Occupancy Rises: Better Days Ahead?
by Zacks Equity Research
Brookdale (BKD) has witnessed 19 straight months of year-over-year increases in weighted average occupancy level.
Humana (HUM) Arm Reaches 250 Senior Primary Care Facilities
by Zacks Equity Research
Humana's (HUM) CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services.
Should You Retain Acadia Healthcare (ACHC) in Your Portfolio?
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is likely to receive support from growth in specialty treatment and acute inpatient psychiatric facilities.
Encompass Health (EHC) to Build New Hospital in Concordville
by Zacks Equity Research
The new inpatient rehabilitation unit is likely to be the 10th hospital of Encompass Health (EHC) in Pennsylvania.
HCA Healthcare (HCA) to Acquire 41 Urgent Care Centers in Texas
by Zacks Equity Research
HCA Healthcare (HCA) expects the acquisition of urgent care centers from FastMed to close by this summer.
Here's Why Hold Strategy is Apt for Centene (CNC) Stock Now
by Zacks Equity Research
Centene's (CNC) health benefit ratio is estimated at 87.1-87.7% for 2023, signaling better operating efficiency.